Eagle Pharmaceuticals

138 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference

• Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)

  11/27/2018

  Eagle to explore ARS indication to treat individuals exposed to high doses of radiation such as nuclear power plant leakage or nuclear weapons; additional research ongoing to evaluate hematopoietic syndrome in certain cancer patients undergoing radiation therapy

• Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

  11/27/2018

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows

• Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

  11/19/2018

  Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows

• Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

  11/1/2018

  Q3 2018 net income was $0.94 per basic and $0.91 per diluted share and adjusted non-GAAP net income was $1.22 per basic and $1.18 per diluted share

• Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization

  10/30/2018

  Q3 2018 preliminary EPS is expected to be $0.94 per basic and $0.91 per diluted share

• Eagle Pharmaceuticals Announces Results of Study for Fulvestrant

  10/30/2018

  Analysis of data shows fulvestrant did not meet bioequivalence criteria

• Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018

  10/25/2018

  Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 third quarter financial results on Thursday, November 1, 2018, before the market opens.

• Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure

  10/3/2018

  The study will be conducted under a Cooperative Research and Development Agreement

• Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference

  9/4/2018

  Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference

• Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke

  8/30/2018

  Preliminary Analysis: RYANODEX Provides Benefit for Patients

• Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies

  8/23/2018

  Achieves #1 ranking for both 3-year EPS and revenue growth

• Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA®

  8/22/2018

  BENDEKA protected by 16 patents running from 2026 through 2033

• Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

  8/7/2018

  Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share

• Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018

  7/25/2018

  Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.

• FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)

  7/9/2018

  Eagle Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI)

• Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

  7/3/2018

  Eagle Pharmaceuticals, Inc. today announced that an additional patent has been issued related to BENDEKA® by the United States Patent and Trademark Office (USPTO).

• Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)

  6/11/2018

  Generic TREANDA entry now not expected until December 2022

• Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June 2018

  5/29/2018

  Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June 2018.

• Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture

  5/16/2018

  Eagle to ship 500ml admixture product immediately